HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Analytical Performance Specifications for Lipoprotein(a), Apolipoprotein B-100, and Apolipoprotein A-I Using the Biological Variation Model in the EuBIVAS Population.

AbstractBACKGROUND:
With increased interest in lipoprotein(a) (Lp[a]) concentration as a target for risk reduction and growing clinical evidence of its impact on cardiovascular disease (CVD) risk, rigorous analytical performance specifications (APS) and accuracy targets for Lp(a) are required. We investigated the biological variation (BV) of Lp(a), and 2 other major biomarkers of CVD, apolipoprotein A-I (apoA-I) and apolipoprotein B-100 (apoB), in the European Biological Variation Study population.
METHOD:
Serum samples were drawn from 91 healthy individuals for 10 consecutive weeks at 6 European laboratories and analyzed in duplicate on a Roche Cobas 8000 c702. Outlier, homogeneity, and trend analysis were performed, followed by CV-ANOVA to determine BV estimates and their 95% CIs. These estimates were used to calculate APS and reference change values. For Lp(a), BV estimates were determined on normalized concentration quintiles.
RESULTS:
Within-subject BV estimates were significantly different between sexes for Lp(a) and between women aged <50 and >50 years for apoA-I and apoB. Lp(a) APS was constant across concentration quintiles and, overall, lower than APS based on currently published data, whereas results were similar for apoA-I and apoB.
CONCLUSION:
Using a fully Biological Variation Data Critical Appraisal Checklist (BIVAC)-compliant protocol, our study data confirm BV estimates of Lp(a) listed in the European Federation of Clinical Chemistry and Laboratory Medicine database and reinforce concerns expressed in recent articles regarding the suitability of older APS recommendations for Lp(a) measurements. Given the heterogeneity of Lp(a), more BIVAC-compliant studies on large numbers of individuals of different ethnic groups would be desirable.
AuthorsNoemie Clouet-Foraison, Santica M Marcovina, Elena Guerra, Aasne K Aarsand, Abdurrahman Coşkun, Jorge Díaz-Garzón, Pilar Fernandez-Calle, Sverre Sandberg, Ferruccio Ceriotti, Anna Carobene
JournalClinical chemistry (Clin Chem) Vol. 66 Issue 5 Pg. 727-736 (05 01 2020) ISSN: 1530-8561 [Electronic] England
PMID32353129 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Copyright© American Association for Clinical Chemistry 2020. All rights reserved. For permissions, please email: [email protected].
Chemical References
  • APOA1 protein, human
  • APOB protein, human
  • Apolipoprotein A-I
  • Apolipoprotein B-100
  • Lipoprotein(a)
Topics
  • Adult
  • Aged
  • Apolipoprotein A-I (blood, standards)
  • Apolipoprotein B-100 (blood, standards)
  • Biological Variation, Individual
  • Female
  • Humans
  • Lipoprotein(a) (blood, standards)
  • Male
  • Middle Aged
  • Reference Values
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: